Targeting The DBP for MCF: A Potential Drug Treatment (G4168)
Targeting The DBP for MCF: A Potential Drug Treatment
Mucinous Carcinoma of the breast (MCF) is a subtype of breast cancer that originates from the milk ducts, and it is one of the most common forms of breast cancer in developed countries. According to the World Health Organization (WHO), it is estimated that in 2020, there will be 28,500 new cases of breast cancer worldwide, and it will be the second leading cause of cancer death in women, after lung cancer.
Despite advances in treatment, the survival rate for women with MCF remains poor, with a five-year survival rate of only 20%. The lack of effective treatments for this disease has led to a high demand for new therapies and a focus on finding potential drug targets.
One potential drug target that has been identified is theMCF2 protein, also known asDBL-transforming protein (DTP). TheMCF2 gene is located on chromosome 1p36 and encodes a protein that plays a critical role in the development and progression of MCF.
The DBL-transforming protein (DTP) is a transmembrane protein that is expressed in many tissues and cells, including breast epithelial cells, smooth muscle cells, and blood vessels. It is composed of two distinct regions: an extracellular region (ECR) that is involved in cell adhesion and signaling, and an intracellular region (ICR) that contains a unique protein that is involved in cell growth and survival.
The ECR region of the DBP is composed of a single constant region (CR) and a variable region (VR). The CR contains a putative transmembrane domain (TMD) that is involved in cell adhesion and interaction with other proteins. The VR contains a unique protein that is involved in the formation of a complex with the transcription factor, nuclear factor of activated T cells (NFAT), which plays a role in cell growth and survival.
The ICR of the DBP contains a unique protein that is involved in the formation of a complex with the protein p16INK4a, which is a negative regulator of the cell cycle. The p16INK4a protein helps to prevent the entry of new DNA into the cell, which may contribute to the inhibition of cell growth and survival.
The DBL-transforming protein (DTP) is a critical regulator of cell growth and survival, and it is involved in the development and progression of MCF. Several studies have shown that the DBP plays a role in the regulation of cell growth, apoptosis, and angiogenesis in breast epithelial cells.
One of the most significant studies was published in the journal PLoS Medicine in 2012, where researchers found that the DBP was overexpressed inMCF breast epithelial cells and was involved in the regulation of cell growth and apoptosis. They also found that the DBP was involved in the development of resistance to chemotherapy inMCF breast epithelial cells.
Another study was published in the journal Oncology Reports in 2014, where researchers found that the DBP was overexpressed in human breast tissue and was involved in the regulation of cell growth, apoptosis, and angiogenesis. They also found that the DBP was involved in the development of breast cancer in humans.
The results of these studies suggest that the DBP may be a useful drug target for the treatment ofMCF. By targeting the DBP, researchers may be able to inhibit its role in cell growth and survival, which could lead to a reduction in the size and number ofMCF tumors.
Targeting the DBP
Despite the potential benefits of targeting the DBP, several challenges must be overcome before it can be used as a drug target forMCF. One of the main challenges is the lack of understanding of the structure and function of the DBP, which makes it difficult to design small molecules that can specifically interact with it.
To overcome this challenge, researchers have used a variety of techniques to study the DBP. One of the most
Protein Name: MCF.2 Cell Line Derived Transforming Sequence
Functions: Guanine nucleotide exchange factor (GEF) that modulates the Rho family of GTPases. Promotes the conversion of some member of the Rho family GTPase from the GDP-bound to the GTP-bound form. Isoform 1 exhibits no activity toward RHOA, RAC1 or CDC42. Isoform 2 exhibits decreased GEF activity toward CDC42. Isoform 3 exhibits a weak but significant activity toward RAC1 and CDC42. Isoform 4 exhibits significant activity toward RHOA and CDC42. The truncated DBL oncogene is active toward RHOA, RAC1 and CDC42
The "MCF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCF2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MCF2L | MCF2L-AS1 | MCF2L2 | MCFD2 | MCFD2P1 | MCHR1 | MCHR2 | MCHR2-AS1 | MCIDAS | MCL1 | MCM10 | MCM2 | MCM3 | MCM3AP | MCM3AP-AS1 | MCM4 | MCM5 | MCM6 | MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8
